Northwire Canada EditionTuesday, July 14, 2026
Sign inSubscribe
Northwire
⌕
WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8% WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8%
Earnings

MediPharm Advances Global Reach in Q3 2025 with Double-Digit Revenue Growth and Strong International Medical Cannabis Gains

By The Northwire Desk — AI Analysis Nov 13, 2025 · 08:00 LABS · 0.07 MEDIPHARM LABS CORP. J
LABS · Price

Executive Summary

  • MediPharm Labs reported Q3 2025 revenue of $11.4 M, a 17% year‑over‑year increase and 83% growth in international medical cannabis sales, which now represent 56% of total revenue.
  • Operating expenses fell 19% YoY to $4.4 M; adjusted EBITDA was a loss of $1.1 M but improved sequentially.
  • Cash balance rose to $10.6 M, and the company remains virtually debt‑free with two owned production facilities valued at >$15 M.

Key Details

  • Revenue: $11.4 M (up $1.6 M YoY, +17%).
  • International Medical Cannabis Revenue: $6.4 M (56% of total), up 83% YoY.
  • Canadian Adult‑Use & Wellness Revenue: $1.8 M (↑4% YoY, ↑9% QoQ).
  • Gross Profit: $2.6 M (margin pressure from product mix).
  • Operating Expenses: $4.4 M (↓19% YoY, ↓35% QoQ).
  • Adjusted EBITDA: –$1.1 M for Q3 2025 (improved by $0.3 M YTD vs prior year).
  • Cash Balance: $10.6 M at quarter end (up $0.2 M from Q2 2025), supported by $0.4 M asset sales.
  • Debt Position: Virtually debt‑free; two production facilities owned outright, appraised >$15 M.
  • Product Updates: Launched metered‑dose inhalers in Australia; expanded domestic inhaler line to include minor cannabinoids; future launches planned for other international markets (e.g., UK).
  • Conference Call/Webcast: Thursday, Nov 13 2025 at 10:00 am ET. Dial‑in: North America Toll‑Free (888)330‑2454; International +1 (240) 789‑2714; Conference ID 4921762. Replay available on company website.
  • Management Comments: CEO David Pidduck highlighted strength of international strategy; CFO Greg Hunter emphasized revenue growth, expense discipline, and cash management.

Notable Quotes

“Our third quarter results reflect the strength of our international strategy, and the resilience of our differentiated business model,” – David Pidduck, CEO.

“We maintained our disciplined approach to expense and cash management, reducing operating expenses by 19% versus prior year… while increasing our cash balance to $10.6 million,” – Greg Hunter, CFO.

Read the original news release →

More from MEDIPHARM LABS CORP. J

May 28, 2026 · 08:00

MediPharm Labs Turns EBITDA Positive Amidst Revenue Contraction and Governance Shifts

Regulatory May 13, 2026 · 07:30

MediPharm Labs scrapes to adjusted EBITDA profitability in Q1 2026, but a veteran affairs reimbursement cut looms large over its direct-to-patient business.

Earnings Apr 27, 2026 · 08:30

US Rescheduling Confirmed, But Canadian Revenue Headwinds Loom

Regulatory Mar 30, 2026 · 07:45

MediPharm Posts Margin Recovery and Steady International Growth, Yet Profitability Remains Elusive

Earnings Mar 25, 2026 · 19:05

MediPharm Delivers Margin Recovery and Near-Breakeven EBITDA as International Sales Offset Domestic Stagnation

Earnings Jan 19, 2026 · 08:00

MediPharm Labs Announces CEO Transition: David Pidduck to Step Down; CFO Greg Hunter Appointed Interim CEO

Management